Background. Empirical antifungal therapy is the standard treatment for persistent or relapsing antibioticresistant neutropenic fever. However, overtreatment resulting in increased toxicity and treatment-related cost is a major shortcoming of such therapy. We assessed the feasibility of a "preemptive" approach based on the incorporation of sensitive, noninvasive diagnostic tests for consecutive high-risk neutropenic patients who had received fluconazole prophylaxis while avoiding empirical therapy.
Invasive fungal infections (IFIs) are major causes of morbidity and mortality in neutropenic patients who receive chemotherapy for hematological malignancies or who undergo allogeneic hematopoietic stem cell transplantation. In patients with IFI who have received fluconazole prophylaxis, molds-in particular, Asper-gillus species-have become the most likely fungal pathogens [1] [2] [3] . Unfortunately, early diagnosis remains a challenge, given the low sensitivity of microbiological culture techniques and the low specificity of standard radiological tools, especially in neutropenic patients [4] . Therefore, infections are often far advanced at the time of diagnostic confirmation, and overall outcome is poor [5, 6] .
Empirical antifungal therapy is considered standard practice of care in neutropenic patients with fever that persists or recurs while they are receiving broad-spectrum antibiotics and has repeatedly been endorsed by consensus guidelines [7, 8] . The aim is to ensure that patients with possible IFI receive therapy early in the course of the disease, because early initiation of therapy seems to improve the survival rate [9] [10] [11] [12] [13] [14] [15] . As a result, as many as 40%-50% of the high-risk neutropenic population may receive empirical antifungal therapy, whereas the true incidence of IFI appears to be 10%-15% [16] .
Overtreatment, as well as the negative effect of delaying therapy until disease is proven, could be overcome by a preemptive approach. Such a strategy targets the population in which there is sufficient evidence of pathogen invasion but no manifest symptomatic disease. Progress could come from the incorporation of non-culture-based microbiological techniques, including screening for circulating Aspergillus galactomannan with an EIA and the early use of high-resolution thoracic CT scanning (HRCT). Both tools have a high diagnostic accuracy in neutropenic adults [17] [18] [19] [20] [21] [22] [23] . The aim of our prospective study was to assess the feasibility of a combined EIA/HRCT-based preemptive strategy (while avoiding administration of empirical antifungal therapy) in patients with cancer and prolonged neutropenia.
MATERIALS AND METHODS
Study population. From 1 January 2003 to 31 January 2004, consecutive adult patients (age, 116 years) admitted to the Leukemia and Transplantation Unit of the University Hospital of Leuven (Leuven, Belgium) were included in the study. Patients were eligible for the study if they had received chemotherapy for acute leukemia or myelodysplastic syndrome while having an expected absolute neutrophil count of ! 9 0.5 ϫ 10 cells/L for at least 10 days or if they underwent myeloablative allogeneic hematopoietic stem cell transplantation. Patients who had aplastic anemia or who underwent autologous or nonmyeloablative allogeneic hematopoietic stem cell transplantation were excluded. The study protocol was approved by the institutional review board of the hospital; informed consent was obtained from all patients.
Study procedures. Patients were hospitalized in single rooms with high-efficiency particulate air filters from the start of therapy until neutrophil recovery (absolute neutrophil count, у cells/L). Antimicrobial prophylaxis consisted of flu-9 0.5 ϫ 10 conazole (400 mg daily) and levofloxacin (250 mg daily). Patients were surveyed for the development of fever (a temperature of 138ЊC recorded twice or 138.5ЊC recorded once) and for the presence of signs and symptoms of IFI. Surveillance cultures for bacterial and fungal growth from stool and urine samples and oral washes were performed weekly; standard chest radiographs were obtained at hospital admission and once to twice weekly (with a portable machine) thereafter in the room. Neutropenic fever was treated with broad-spectrum antibiotics (i.e., cefepime or meropenem), in accordance with published guidelines [7] . Additional blood cultures, sputum cultures, and cultures of samples from infected sites were performed as clinically indicated. One set of blood cultures was performed daily for patients who received steroids, irrespective of the presence of fever. Vancomycin was added to the treatment regimen for patients who were colonized with methicillin-resistant Staphylococcus aureus, who had clinically infected catheter entry-sites, or whose blood cultures yielded gram-positive bacteria. Persistent neutropenic fever was not an indication for the use of glycopeptides [24] . Metronidazole was added in cases of necrotizing gingivitis, perianal abscess, or intraabdominal sepsis if it was not treated with meropenem. More than 1 treatment episode could be included per patient, but once IFI was diagnosed, patients were no longer eligible for a subsequent inclusion until complete resolution of the infection. Findings that triggered a diagnostic evaluation for IFI were as follows: (1) neutropenic fever refractory to 5 days of broadspectrum antibiotic treatment or unexplained fever relapsing after at least 48 h of defervescence while the patient was still neutropenic and still receiving antibiotics, (2) clinical signs and/ or symptoms suggestive of IFI, (3) appearance of a new pulmonary infiltrate while the patient was receiving treatment with broad-spectrum antibiotics or steroids, (4) isolation of molds or demonstration of hyphae in respiratory specimens, and (5) two consecutive galactomannan EIA assays with an optical density index of у0.5 (figure 1). The diagnostic evaluation included the following: (1) HRCT (with or without sinus CT) within 24 h after request, in accordance with a previously described protocol [25] ; and (2) bronchoscopy with bronchoalveolar lavage in patients without severe hypoxemia. Bronchoalveolar lavage samples were submitted for microscopic examination and culture for bacteria, fungi, mycobacteria, and Legionella species. Cytomegalovirus, herpes simplex virus, varicella zoster virus, Toxoplasma gondii, Pneumocystis jiroveci, Mycoplasma pneumoniae, and Chlamydia pneumoniae were detected by PCR. Endobronchial biopsies were not performed in patients with cytopenia. Other diagnostic procedures could be performed when clinically indicated.
Autopsy was pursued for all fatalities. Specimens were stained with periodic acid-Schiff or Gomori-methenamine silver stain. Galactomannan EIA. Six milliliters of blood was collected daily in tubes that contained EDTA until the resolution of neutropenia or, in cases of invasive aspergillosis, until the end of hospitalization or death. Samples were stored at Ϫ20ЊC and were analyzed thrice weekly (with the Platelia Aspergillus EIA; Bio-Rad Laboratories) by technicians who were unaware of the clinical status of the patient. Processing of the sample and optical density measurements were performed with a semiautomatic analyzer (Behring ELISA processor III; Dade Behring), in accordance with the recommendations of the manufacturer [26] . All reagents were purchased from Bio-Rad Laboratories. Positive, negative, and threshold controls were included in each run. Results were recorded as an index relative to the optical density of the control sample obtained in the same run. An index of у0.5 was considered to be a positive result if it was confirmed with a subsequent sample. After analysis, results were immediately reported back to the clinicians by fax.
Treatment algorithm. Only patients with у2 consecutive EIA assays with an index of у0.5 (irrespective of clinical and radiological findings) or with CT findings suggestive of IFI that were supported by a culture or microscopic evaluation positive for molds received liposomal amphotericin B (5 mg/kg iv). In the absence of the aforementioned criteria, suggestive signs and/ or symptoms, persistent or relapsing neutropenic fever, and new pulmonary infiltrates were not indications for antifungal therapy. Patients who were refractory to at least 10 days of primary treatment (clinical, radiological, and serological progression) or who were intolerant of liposomal amphotericin B (because of nephrotoxicity or infusion-related side effects) could have their regimen switched to other licensed antifungal agents.
Analysis. The primary aim of this nonrandomized pilot study was to evaluate the feasibility of a preemptive approach, as opposed to a fever-driven empirical strategy-that is, how many patients with IFI would receive a misdiagnosis and how many would receive treatment with use of this specific preemptive algorithm, compared with how many would receive treatment with the use of empirical antifungal therapy? Episodes were classified on the basis of the European Organization for the Research and Treatment of Cancer/Mycosis Study Group consensus criteria using an EIA index cutoff of 0.5 [27] . Responses in patients with proven and probable IFI were assessed on the basis of published criteria [28] . Descriptive statistics are reported. Continuous variables are summarized as means ‫ע‬ . SDs
RESULTS
A total of 136 treatment episodes (88 patients) were investigated. Baseline demographic and clinical characteristics are presented in table 1. All episodes involved patients with multiple risk factors for IFI in addition to prolonged neutropenia, such as use of steroids, older age, prolonged use of broad-spectrum antibiotics, receipt of high-dose cytarabine, and uncontrolled malignancy.
Classification of study episodes. Neutropenic fever developed in 117 episodes (86%) (figure 2). After administration of broad-spectrum antibiotics, patients defervesced within 5 days (mean time to defervescence, days) in 82 episodes, 1.84 ‫ע‬ 1.29 whereas fever persisted for 15 days (mean time to defervescence, days; range, 6-26 days) in the remaining 30 11.7 ‫ע‬ 4.6 evaluable episodes (18 cases of fever of unknown origin, 7 cases of bacteremia with documented microbiological eradication, and 5 cases of clinically documented infection). Overall, 5 episodes were considered to be nonevaluable as a result of confounding causes of fever (i.e., the episode was drug related, disease related, or transfusion related). Time to defervescence for the whole group was days. Antibiotic therapy was also 5.1 ‫ע‬ 6.1 started for 6 of 19 nonfebrile episodes that were due to bacteremia experienced while patients were receiving steroids or due to a pre-existing infection. In 54 successfully treated episodes, patients remained afebrile, whereas a second episode of neutropenic fever occurred in 28 treatment courses. In these latter episodes, the etiology of fever remained unexplained (11 cases) or was attributed to a breakthrough bloodstream infection (17 cases figure 2 . In the febrile neutropenic group (117 episodes), only 9 episodes were treated preemptively, although at least 41 episodes qualified for empirical antifungal therapy; this represents a reduction in the use of antifungals from an estimated 35% to 7.7% (difference, 27.3%; 95% CI, 9.9%-37.2%). In addition, 10 nonfebrile episodes or febrile episodes with alternative explanations received preemptive therapy on the basis of seropositivity.
Positive galactomannan EIA results were the primary triggers for further evaluation in 16 cases: supportive findings were seen on the first CT (13 episodes) or on a follow-up CT 1 week later (3 episodes). Persistent fever was the primary trigger in 3 remaining episodes; although the initial CT was unrevealing, follow-up CT revealed a classical halo sign. Suggestive clinical signs and/or symptoms, a new pulmonary infiltrate, or isolation of molds from respiratory specimens were never the trigger for further diagnostic exploration. The temporal relationship between positive EIA results and the presence of suggestive abnormalities on CT could not be investigated, because antigenemia was a trigger for performing CT. Baseline characteristics and outcomes are listed in table 2. Per protocol, all of the patients who experienced these episodes received antifungal therapy. Cases of proven invasive aspergillosis were treated for a median of 34 days (range, 6-75 days); cases of probable invasive aspergillosis were treated for a median of 25 days (range, 11-66 days). All surviving patients received oral maintenance therapy with azoles with activity against molds.
The remaining 117 episodes (3251 samples; mean, 27.7 ‫ע‬ samples per episode; range, 5-53 samples per episode) form 8.8 the seronegative group; 10 samples (0.3%) had optical density indices of у0.5, but the results were not confirmed with a subsequent sample. Fourteen seronegative episodes (12%) were classified as possible fungal infection; culture and microscopic examination of bronchoalveolar lavage samples from 12 of these cases yielded Pseudomonas aeruginosa (2 episodes), methicillinresistant S. aureus (1 episode), or no causative pathogen, including coagulase-negative staphylococci (9 episode). None of these 14 episodes were treated with antifungals. In accordance with European Organization for the Research and Treatment of Cancer/Mycosis Study Group criteria, not a single seronegative episode was diagnosed as proven or probable invasive aspergillosis. However, 2 cases of breakthrough C. glabrata fungemia were detected by conventional blood culture techniques and were treated successfully with caspofungin. In addition, a patient with refractory leukemia who developed a sudden brain hemorrhage (without fever or any other clinical finding suggestive of IFI) proved to have disseminated zygomycosis at autopsy. Thus, 1 (4.5%) of 22 cases of IFI remained undiagnosed antemortem, and the affected patients did not receive adequate therapy.
Survival and autopsy data. The overall mortality rate was 18.1% (16 of 88 patients). Seven deaths (41.1%) occurred among patients with positive EIA results. Although autopsy demonstrated hyphal tissue invasion in 6 of 7 patients, invasive aspergillosis was considered the primary cause of death in 2 patients only. For the remaining 4 cases, invasive aspergillosis was a contributing factor, whereas refractory leukemia, disseminated toxoplasmosis, cytomegalovirus disease, and graft failure complicated by bacterial superinfections were the primary causes of death. Interestingly, at autopsy, these latter patients were shown to have organizing necrotic pulmonary nodules without angio-invasion, and all had a favorable serological response after antifungal treatment. None of these patients had signs of extrapulmonary dissemination at autopsy. The only fatal probable case showed a favorable serological response, but the patient died of refractory leukemia; autopsy could not demonstrate fungal involvement. Nine patients (12.7%) from the EIA-negative group died. Autopsy-proven causes of death were attributed to worsening underlying disease or to other nosocomial complications. Except for the case of zygomycosis, no undetected cases of IFI were found. At 3 months, the survival rate was 63.6% for patients with IFI and 63.1% for patients with invasive aspergillosis (it was 76.9% for patients with complete remission of their underlying disease or residual disease vs. 30% for patients with refractory disease). Overall, seronegativity was achieved in 68.4% of episodes of invasive aspergillosis (table 2) .
DISCUSSION
Persistent or recurrent unexplained neutropenic fever refractory to antibiotic therapy may represent an IFI and is considered a valid indication for empirical antifungal therapy [8] [9] [10] [11] [12] [13] [14] [15] . However, a wide range of biological processes-some infectious, and many noninfectious-can cause fever, including inadequately managed nonfungal infections, drugs, malignancies, graftversus-host disease, and neutrophil recovery. Conversely, the use of steroids as part of cytoreductive regimens may result in the absence of fever, even in patients with disseminated fungal disease [30] . Thus, we must try to more accurately distinguish between patients truly in need of antifungal therapy and those who do not need antifungals. This prospective study, which involved adult hematology patients who received fluconazole prophylaxis and who had wellidentified risk factors for invasive mold infection, challenges widely accepted empirical concepts by using a strategy based on intensive screening for galactomannan and HRCT. A purely fever-driven approach would presumably have resulted in administration of empirical antifungal therapy for 35% of febrile neutropenic episodes, whereas use of our algorithm resulted in initiation of treatment with antifungals in only 7.7% of these episodes. This finding underscores the potential for overtreatment, toxicity, and increased treatment-related cost associated with recommending early empirical antifungal therapy. This observation also demonstrates the existence of center-related variability regarding the use of empirical antifungal therapy; our 35% rate of empirical antifungal therapy seems on the low side and might suggest that the risk for IFI may be lower than has previously been anticipated, although the IFI rate in this study (22%) was consistent with literature findings [31] .
Obviously, the feasibility and safety of targeted strategies depend on the availability of reliable diagnostic tools. Our strategy incorporated both screening for circulating galactomannan and early use of HRCT for the detection of invasive aspergillosis, by far the most common fungal pathogen in neutropenic patients who have received fluconazole prophylaxis. Although reported diagnostic accuracies of galactomannan detection have been disappointing in heterogeneous study populations [32] , test performance and reproducibility have been excellent in adult neutropenic patients with a high pretest probability [18] [19] [20] [21] [22] and have been sufficiently robust to be used for determination of who should receive preemptive therapy [33] . The excellent negative predictive value of the EIA allowed us to determine whether antifungal therapy can be withheld in patients with refractory neutropenic fever with no other evidence of IFI. Given the nearly 100% fatal outcome of untreated invasive aspergillosis [2] , it seems unlikely that we failed to detect patients who were truly infected with Aspergillus species, an assumption supported by the lack of undiagnosed cases at autopsy. In addition, positive results were often recorded before the development of fever, which is the trigger for empirical antifungal therapy [20, 25] . Thus, episodes that were not suspected of being invasive aspergillosis (because of absence of fever or presence of confounding factors) were detected early by positive EIA results.
We realize that the exact clinical and pharmaco-economical impact of a preemptive strategy can only be assessed in a randomized, prospective evaluation in which it is compared with an empirical approach. Nevertheless, the results of this pilot study are encouraging and provide rationale for such a challenging study. Achieving seronegativity in almost 70% of neutropenic episodes complicated by invasive aspergillosis is noteworthy, especially because studies indicate that levels of galactomannanemia closely correlate with fungal burden and outcome of therapy [34] [35] [36] . When liposomal amphotericin B is used as primary therapy, particularly encouraging is the 76.9% survival rate at 3 months for the subgroup with complete remission or residual disease of their underlying disease. The 30% survival rate for the "refractory disease" subgroup once more underscores the prognostic importance of underlying disease status and immune reconstitution [2] .
Three observations regarding the EIA warrant additional discussion. First, several factors that interfere with the performance have been identified, including the prophylactic use of mold-active azoles, receipt of empirical antifungal therapy, and the use of piperacillin-tazobactam [20, 37] . Although none of these factors confounded the performance in this study, they may be present in institutions with different policies. Second, we used 0.5 as an index cutoff for EIA positivity, as was recently accepted by the US Food and Drug Administration [20] , but we required at least 2 consecutive positive samples before antifungal therapy was started. Of note, most probable episodes remained seropositive at higher, more conventional cutoffs, and all probable pulmonary cases were supported by suggestive CT findings. Therefore, we hypothesize that, in some cases, the occurrence of high-level antigenemia was prevented by the early institution of antifungal therapy; a similar observation of suppressed expression of antigenemia has been reported in empirically treated patients [20] . Third, the antigen ratio in patients with invasive aspergillosis usually increased from negative (!0.5) to clearly positive (11.0) in the course of 2 or 3 days; thus, twice-or thrice-weekly sampling seems to be frequent enough and would substantially reduce the cost of our preemptive strategy [21] .
The specificity for Aspergillus species in our algorithm may keep clinicians from shifting emphasis to preemptive therapy [38] . However, the 2 cases of breakthrough fungemia were detected by conventional methods, even before the triggering criterion of unexplained relapsing fever was reached. Unfortunately, 1 fatal case of zygomycosis remained untreated; but, given the absence of fever, even an empirical approach would not have rescued this particular patient. Consequently, we feel that a preemptive strategy that targets invasive aspergillosis is feasible and safe and obviates the need for empirical antifungal therapy in high-risk neutropenic patients, provided that adequate Candida prophylaxis is given. Of note, the algorithm cannot be extended to nonneutropenic risk populations of persons who often display a different fungal epidemiology-in particular, solid-organ transplant recipients and allogeneic hematopoietic stem cell transplant recipients treated for graftversus-host disease [39, 40] . For these latter categories, the use of panfungal assays (such as PCR and b-glucan detection) may be more appropriate [41, 42] .
In summary, abandoning empirical antifungal therapy for a preemptive approach spared patients from exposure to expensive and potentially toxic drugs. Alternatively, the treatment algorithm offered effective antifungal control for patients with invasive aspergillosis, even for those not qualifying for empirical antifungal therapy, but it failed to identify non-Aspergillus infections. A randomized trial comparing outcome and costeffectiveness of fever-driven empirical therapy versus an EIAor CT-driven preemptive approach may be in order.
